MDS Nordion signs 17-year contract with Rosenergoatom
19 Ottobre 2007 - 2:00PM
PR Newswire (US)
Contract expansion provides for increased cobalt-60 supply for the
healthcare industry OTTAWA, Oct. 19 /PRNewswire-FirstCall/ -- MDS
Nordion, a leading provider of medical isotopes and
radiopharmaceuticals, signed a 17-year contract for the supply of
cobalt-60 with Rosenergoatom, the operating utility of Russia's
nuclear power plants. This contract expands upon the 2005 agreement
by providing for an increased supply of cobalt-60 to MDS Nordion
until 2024. As a result, MDS Nordion's overall supply will increase
by approximately 30% by 2016. Cobalt-60 is primarily used for the
sterilization of hospital medical supplies and pharmaceuticals to
help prevent patient infection and disease by reducing harmful
bacteria. "As demand for cobalt-60 increases each year, this
contract is great news for the global medical community," said
Steve West, President, MDS Nordion. "It demonstrates MDS Nordion's
ongoing commitment to provide customers a long-term supply to meet
their growing sterilization needs." Cobalt-60 is used worldwide to
sterilize 45% of all disposable medical devices such as surgeons'
gloves, syringes, sutures, and catheters. This sterilization
process has been used for more than 40 years, having been proven
safe, reliable and highly effective. "Rosenergoatom plays an
important role in providing a consistent supply of cobalt-60,"
remarks Valery Lebedev, a Deputy Director General at Rosenergoatom.
"Unlike most power reactors, Rosenergoatom can harvest cobalt-60
while the reactor is in operation. This allows MDS Nordion to more
closely match cobalt-60 supply to customer demand by increasing the
reliability and efficiency of the overall supply chain." About MDS
Nordion MDS Nordion (http://www.mdsnordion.com/) is a world leader
in medical isotopes, radiation and related technologies. It is a
business unit of MDS Inc. (TSX:MDS)(NYSE:MDZ). MDS Inc. is a global
life sciences company that provides market-leading products and
services for the development of drugs and diagnosis and treatment
of disease. We are a leading global provider of pharmaceutical
contract research, medical isotopes for molecular imaging,
radiotherapeutics, and analytical instruments. MDS Inc. has more
than 6,200 highly skilled people in 28 countries. Find out more at
http://www.mdsinc.com/ or by calling 1-888-MDS-7222, 24 hours a
day. About Rosenergoatom Rosenergoatom was established by the
decree of the President of the Russian Federation on September 7th,
1992 as the operating utility of Russia's nuclear power plants.
Rosenergoatom operates all 10 state-owned Russian nuclear power
facilities with a total of 31 nuclear reactors and an installed
electrical capacity of 23,242 Megawatts. Rosenergoatom has also
increased electric and thermal power output and recently
commissioned two new power reactors; Volgodonsk-1 and Kalinin-3.
More information may be found at http://www.rosenergoatom.ru/eng/.
DATASOURCE: MDS Nordion CONTACT: Media: Shelley Maclean, Manager
External Communications, MDS Nordion, (613) 592-3400 ext. 2414, ;
Investors: Sharon Mathers, Senior Vice-President, Investor
Relations and External Communications, MDS Inc., (416) 675-6777 x
34721,
Copyright
Grafico Azioni Mds (NYSE:MDZ)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Mds (NYSE:MDZ)
Storico
Da Lug 2023 a Lug 2024
Notizie in Tempo Reale relative a Mds (Borsa di New York (NYSE)): 0 articoli recenti
Più Mds Articoli Notizie